<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00740545</url>
  </required_header>
  <id_info>
    <org_study_id>RB06.050</org_study_id>
    <nct_id>NCT00740545</nct_id>
  </id_info>
  <brief_title>Prevention of Unexplained Recurrent Abortion by Enoxaparine</brief_title>
  <acronym>PREFIX</acronym>
  <official_title>Essai thérapeutique randomisé Multicentrique en Double Insu, Comparant l'énoxaparine 40mg Versus Placebo, en Une Injection Sous-cutanée Quotidienne, Dans Les Fausses Couches spontanées récurrentes inexpliquées</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Standard investigations fail to reveal any apparent cause in 50% of the cases of recurrent
      spontaneous abortion. Prothrombotic mechanisms were initially evoked. Factor V Leiden,
      Prothrombin G20210A mutation and protein S deficiency are implicated in the meta-analysis of
      Rey (Lancet).However, they do not account for a large number of miscarriages.Gris JC and
      coworkers (Blood 2004)carried out an open trial, low-molecular-weight heparin versus low-dose
      aspirin, in women with one fetal loss and with a constitutional thrombophilic disorder. They
      conclude for a benefit action of Low-molecular-weight heparin. There is actually no trials
      concerning women with unexplained recurrent abortions and without known thrombophilia.
      Nevertheless,aspirin or enoxaparin are often prescribed. It is time to assess these
      practices. We therefore initiate a multisite, double blind randomized study, enoxaparine
      versus placebo, in women without known thrombophilia, which experienced unexplained recurrent
      abortions.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Stopped for futility
  </why_stopped>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alive and Viable Births</measure>
    <time_frame>number of born child healthy</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">258</enrollment>
  <condition>Alive and Viable Births</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>enoxaparine 40 mg daily</intervention_name>
    <description>Women inject ourselves every days with 40 mg of enoxaparine</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Women inject ourselves every days with placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women between 18 and 45 years

          -  2 or more consecutive spontaneous abortions before the 15th week of pregnancy

          -  Unexplained abortions

          -  No maternal or paternal characterized chromosomal aberration

          -  No Anti-phospholipid Syndrome

          -  No anatomical abnormality possibly responsible for abortion

          -  No Factor V Leiden

          -  No Prothrombin G20210A mutation

          -  No protein S deficiency

          -  No protein C deficiency

          -  No Anti thrombin 3 deficiency

          -  Proved pregnancy

        Exclusion Criteria:

          -  Contraindications of enoxaparine 4000 U per day

          -  Women with risk of venous thromboembolism during pregnancy

          -  No regular anticoagulation or antiplatelet treatment

          -  Blood Hemoglobin level below 10g/dl

          -  Blood platelet level below 150 000/mm3

          -  Creatinine clearance below 30ml/mn

          -  Anomaly of the coagulation tests

          -  No informed consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisabeth Pasquier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Internal Medecine and pneumology department of university hospital of Brest (FRANCE)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Universitaire de Caen</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Bretagne Sud</name>
      <address>
        <city>Lorient</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Nord Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de St Etienne</name>
      <address>
        <city>Saint Etienne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2008</study_first_submitted>
  <study_first_submitted_qc>August 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2008</study_first_posted>
  <last_update_submitted>March 4, 2015</last_update_submitted>
  <last_update_submitted_qc>March 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

